The biopharmaceutical industry’s positive regulatory momentum carried on through 2019, despite an early-year government shutdown, a data manipulation scandal around a high-profile approval, and many months without permanent leadership at the FDA.
Access options
Subscribe to Journal
Get full journal access for 1 year
66,34 €
only 5,53 € per issue
All prices include VAT for Germany.
Rent or Buy article
Get time limited or full article access on ReadCube.
from$8.99
All prices are NET prices.



Author information
Affiliations
Rights and permissions
About this article
Cite this article
Morrison, C. Fresh from the biotech pipeline—2019. Nat Biotechnol (2020). https://doi.org/10.1038/s41587-019-0405-7
Published: